GSK's gonorrhoea vaccine receives FDA's 'fast-track' designation

[June 27, 2023]  (Reuters) - GSK's vaccine candidate to treat sexually transmitted infection gonorrhoea has been granted a fast-track designation by the U.S. Food and Drug Administration (FDA), the British drugmaker said on Tuesday.

The Neisseria gonorrhoeae investigational vaccine is currently at a mid-stage trial and aims to demonstrate efficacy of the vaccine in healthy adults who are at high risk of the infection, the company said in a statement.

The FDA's "Fast Track" designation is intended to facilitate the development and expedite the review of potentially important new drugs and vaccines to treat or prevent serious conditions with unmet medical needs.

(Reporting by Radhika Anilkumar in Bengaluru; Editing by Rashmi Aich)

GSK logo is displayed in this illustration taken January 17, 2022. REUTERS/Dado Ruvic/Illustration/File Photo/File Photo

[© 2023 Thomson Reuters. All rights reserved.]This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.